IkT-148009 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05424276 (ClinicalTrials.gov)	May 23, 2022	10/6/2022	A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease	A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease	Parkinson Disease	Drug: IkT-148009;Drug: Placebo	Inhibikase Therapeutics, Inc.	NULL	Recruiting	30 Years	75 Years	All	120	Phase 2	United States
2	NCT04350177 (ClinicalTrials.gov)	February 16, 2021	26/12/2019	A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients	A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients	Healthy Elderly;Parkinson Disease	Drug: IkT-148009;Drug: Placebo	Inhibikase Therapeutics, Inc.	NULL	Completed	55 Years	70 Years	All	101	Phase 1	United States